|Bid||261.26 x 1100|
|Ask||281.98 x 800|
|Day's Range||265.70 - 277.33|
|52 Week Range||119.01 - 319.19|
|Beta (5Y Monthly)||1.36|
|PE Ratio (TTM)||59.91|
|Earnings Date||Feb 04, 2021 - Feb 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||312.40|
Abiomed to hold fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference.
When it comes to consistent profitability, long-term growth, large competitive moats, and innovation, medical device companies can provide better returns in the long run. In particular, DexCom (NASDAQ: DXCM), Medtronic (NYSE: MDT), and Abiomed (NASDAQ: ABMD) have beaten the NASDAQ Biotechnology Index handily over the last five years. If you had to check your blood glucose level a few times per day, you'd probably grow tired of pricking your finger to draw a drop of blood.
Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.